Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.
Read Full NewsCuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.
Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.
New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!
Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors
Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia
Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA
1.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
2.
AI is useful in low-resource areas for triaging breast masses.
3.
A new device enhances liquid biopsy.
4.
Neural networks and label-free microscopy enable accurate detection of pancreatic tumors
5.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
1.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
2.
How to Prevent Tumor Lysis Syndrome in Cancer Patients
3.
Breast Cancer Recovery: Fashion, Function, and Healing Beyond Scars
4.
The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options
5.
Managing Acute Respiratory Failure in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Current Scenario of Cancer- Q&A Session to Close the Gap
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge